ASX:LDX

Lumos Diagnostics (LDX) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

About Lumos Diagnostics

Lumos Diagnostics Holdings Limited, a contract research and development company, develops, manufactures, and commercializes rapid point-of-care (POC) diagnostic products for diagnosis and management of infectious diseases in the United States and Australia. The company's products include FebriDx, a POC diagnostic test for detecting and differentiating viral and bacterial respiratory infections; ViraDx, a three-in-one POC test for influenza A, influenza B, and COVID-19.; and CoviDx, a rapid antigen test for COVID-19. It also offers desktop readers, disposable readers, and Lumos Leelu readers. Lumos Diagnostics Holdings Limited was founded in 2004 and is based in Melbourne, Australia.

LDX Stock News Headlines

The asset beating inflation by 4x
"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.
Lumos Diagnostics Holdings Ltd (LDX)
Lumos Diagnostics Holdings Limited (LDX.AX)
Lumos Diagnostics Holdings Ltd.
Lumos Receives US FDA Clearance for FebriDx®
The asset beating inflation by 4x
"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.
See More Headlines
Receive LDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lumos Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostics & Research
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$-8,820,000.00
Net Margins
-107.38%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$8.21 million
Book Value
A$0.02 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
0.74
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Mr. Samuel Lanyon
    Executive Chairman
  • Mr. Douglas Ward
    CEO, MD & Director
  • Mr. Barrie Lambert
    Chief Financial Officer
  • Dr. Sacha Dopheide Ph.D.
    Chief Technology Officer
  • Ms. Jennifer Christiansen
    Vice President of Corporate Marketing & Communications
  • Ms. Sarah Glubka
    Senior Director of Human Resources
  • Mr. Paul Kase
    Senior Vice President of Commercial Operations
  • Ms. Tracy Weimar BA
    MBA, Company Secretary

This page (ASX:LDX) was last updated on 5/4/2024 by MarketBeat.com Staff

From Our Partners